New diabetes clinical trial: A Study to Evaluate the Efficacy, Safety, and Tolerability Of Once-Weekly CT-388 Administered For 48 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Published on: July 28, 2024 at 11:00PM
Conditions: Obesity; Overweight
Interventions: Drug: CT-388; Drug: Placebo
Sponsors: Carmot Therapeutics, Inc.; Hoffmann-La Roche
Not yet recruiting
https://ift.tt/dofVUjN